Williams M Lidke DS Hartmann K George TI 2019 Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against the PD-1/PD-L1 interaction have gained clinical importance. PD-L1 expression has been assessed in a few studies on mastocytosis. We review this literature and the need for further investigation of the tumor-immune interaction in mastocytosis. application/pdf https://sonar.ch/global/documents/54056 eng info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms20092362 info:eu-repo/semantics/altIdentifier/pmid/31086024 info:eu-repo/semantics/openAccess International journal of molecular sciences. - 2019 PD-1 PD-L1 immune checkpoint mastocytosis Animals B7-H1 Antigen Biomarkers, Tumor Humans Mastocytosis Programmed Cell Death 1 Ligand 2 Protein PD-L1 Expression in Mastocytosis. http://purl.org/coar/resource_type/c_6501